Navigation Links
Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases
Date:9/6/2007

A partnership between Kent State University, Summa Health System and IC-MedTech Inc. has yielded an innovative liquid crystal technology that offers the promise of new drugs which may more effectively manage cancer and other diseases.

The American Cancer Society estimates that nearly 1.5 million new cases of cancer will be diagnosed this year. This crisis has caused the National Cancer Institute to establish a goal of eliminating suffering and death due to cancer by the year 2015.

Kent State University, Summa Health System and IC-MedTech Inc. have taken steps toward that goal. Their collaborative efforts have yielded an innovative liquid crystal technology that offers the promise of new drugs which may more effectively manage cancer and other diseases.

Dr. Chun-che Tsai, Kent State professor of chemistry; Dr. Jim Jamison, manager of Urology, Obstetrics and Gynecology Core Basic Research Laboratory for Summa Health System; and Mr. Tom Miller, president of IC-MedTech Inc., a California-based biotechnology company, have developed a new paradigm in drug discovery based on the pharmacologic properties of liquid crystals called Liquid Crystal Pharmaceuticals or LCPs.

Recently, the team gathered at Kent State Universitys Office of Technology Transfer to file applications for two new patents: one for a new LCP-based anti-tumor drug called Tolecine and another for a formulation that combines Tolecine and another LCP, Apatone®.

The path-breaking discoveries of Dr. Tsai and his colleagues offer compelling proof of the value of university research and the enormous good that can come from collaborations between universities and the private sector, says Kent State President Lester A. Lefton. As Kent State researchers tackle cancer and a host of other real-world ills and issues, they are bringing their leading-edge knowledge and creativity to our students and playing a significant role in economic development.

Though best
'/>"/>

Contact: Melissa Edler
medler@kent.edu
330-672-8589
Kent State University
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Researchers find how protein allows insects to detect and respond to pheromones
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. NYU researchers simulate molecular biological clock
5. Researchers reveal the infectious impact of salmon farms on wild salmon
6. Researchers identify target for cancer drugs
7. Vital step in cellular migration described by UCSD medical researchers
8. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
9. UCSD researchers maintain stem cells without contaminated animal feeder layers
10. Researchers discover molecule that causes secondary stroke
11. Researchers find missing genes of ancient organism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... majority owned subsidiary of Avisio, Inc. acquired an ... , The technology is based on an ... e.g. mosquitos and black flies, utilize their olfactory ... animals and humans. CO2, which is a major ... insect to its prey. , Developed by ...
(Date:2/8/2010)... Mediterranean diet may help people avoid the small areas ... thinking and memory, according to a study released today ... Neurology,s 62nd Annual Meeting in Toronto April 10 to ... people who ate a Mediterranean-like diet were less likely ... tissue linked to thinking problems. , The Mediterranean ...
(Date:2/8/2010)... With the recent election of Senator ... in the loss of the Democratic supermajority, the urgency ... universal coverage for the majority of uninsured Americans has ...  President Obama recently noted the country is closer than ... for many a long sought after social reform, and ...
Breaking Biology News(10 mins):Mediterranean diet may lower risk of brain damage that causes thinking problems 2S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now? 2S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now? 3S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now? 4S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now? 5S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now? 6S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now? 7S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now? 8S&P Equity Research; Health Care Reform After The Buzzsaw - Where Are We Now? 9Census Bureau Releases Comprehensive Health Insurance Coverage Estimates by County 53506 1Census Bureau Releases Comprehensive Health Insurance Coverage Estimates by County 53506 2Hard to Treat Diseases Inc 28HTDS 29 Experiments with Hyperbaric Oxygenation 28HBO 29 Traumatic Brain Injury 53504 1Hard to Treat Diseases Inc 28HTDS 29 Experiments with Hyperbaric Oxygenation 28HBO 29 Traumatic Brain Injury 53504 2Hard to Treat Diseases Inc 28HTDS 29 Experiments with Hyperbaric Oxygenation 28HBO 29 Traumatic Brain Injury 53504 3Hard to Treat Diseases Inc 28HTDS 29 Experiments with Hyperbaric Oxygenation 28HBO 29 Traumatic Brain Injury 53504 4Exercise Is Healthy for Mom and Child During Pregnancy 53502 1Exercise Is Healthy for Mom and Child During Pregnancy 53502 2Exercise Is Healthy for Mom and Child During Pregnancy 53502 3
... reported findings that offer a surprising new twist to ... select the flowers from which they collect nectar. When ... flowers entirely alone but instead copy the choices of ... their behavior when dealing with flowers of unfamiliar plant ...
... paths some 5 million to 6 million years ago, we ... and acquired a knack for abstract thought while our next ... to construct tree-bound nests high above the forest floor. We ... sequence level, yet scientists predict that both species should harbor ...
... River varies in time, what causes those variations, and ... deforestation is a focus of study for scientists at ... in the last several decades have led to significant ... eastern and southern portion of the basin. By using ...
Other Biology News:Can our genes tell the story of our divergence? 2Assessing the Amazon River's sensitivity to deforestation 2
(Date:2/9/2010)... Feb. 9 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc.,(NYSE ... an international,biopharmaceutical company with operations in the U.S. ... cell collection network has expanded into the southwestern,region ... physician group at Westlake,Orthopaedics Spine & Sports ("Westlake") ... is on,track to achieve its target of 10 ...
(Date:2/8/2010)... /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical Co., Inc., (NYSE Alternext: TPI), ... based in Chengdu, China ,today announced fiscal results ... . , , -- Q2 2010 ... 24.8% to $2.6 ... basis, -- Cash and Equivalents of ...
(Date:2/8/2010)... label-free biomolecular interaction analysis now offers surface chemistries for: ... and Protein G for coupling antibodies. , ... ... February 8, 2010 -- Silicon Kinetics Inc., the pioneering ... first 3D biosensor surface for label-free biomolecular interaction analysis, ...
(Date:2/8/2010)... NEW ORLEANS , Feb. 8 /PRNewswire-FirstCall/ ... worldwide developer and marketer of diagnostic test kits, and ... of the collaborative effort to combat viral hemorrhagic fever ... $800,000 in contract revenue for Corgenix over the ... of Health (NIH) has awarded a five-year contract totaling ...
Breaking Biology Technology:Busy Southwestern Orthopedic Practice Joins the NeoStem Stem Cell Collection Network 2Busy Southwestern Orthopedic Practice Joins the NeoStem Stem Cell Collection Network 3Busy Southwestern Orthopedic Practice Joins the NeoStem Stem Cell Collection Network 4Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 2Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 3Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 4Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 5Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 6Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 7Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 8Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 9Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 10Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 11Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 12Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 13Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 14Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 15Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 16Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results 17Silicon Kinetics Announces New Biosensor Chips With Wide Palette of Surface Chemistries 2Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 2Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 3Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 4Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 5Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 6Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents 7
... Nov. 26 Evalve, Inc., the leader in,the ... cardiac valves,announced today that the first three patients ... the University of Hull, Castle Hill Hospital,in the ... commercially,available medical device which provides a non-surgical mitral ...
... an update on internal policy and clinical, ... Symbol: RVX , , CALGARY, ... that the previously announced internal blackout trading restriction of April ... regional and global partnerships are actively ongoing and should the ...
... Nov. 26 Thomas K. Equels, President and Managing,Director ... the board of directors,for Hemispherx BioPharma, Inc. (Amex: ... manufacture and clinical development,of new drug entities for the ... Equels, legal practice is devoted ...
Other Biology Technology:First United Kingdom Patients Treated With Percutaneous MitraClip(R) System 2First United Kingdom Patients Treated With Percutaneous MitraClip(R) System 3Resverlogix Board of Directors Update 2Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors 2Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors 3
...
...
... allow for the rapid isolation of DNA from ... slice in the spin filter, centrifuge for 3 ... recovered. There is no need to melt agarose ... can also be used for buffer exchange, primer ...
ChemiArray Human Cytokine Antibody Array VII, 60 cytokines per membrane...
Biology Products: